Hepatology
Hepatology
3 years ago

Pembrolizumab for Metastatic Hepatocellular Carcinoma Following Live Donor Liver Transplantation: The Silver Bullet?

Rela, Farouk, Vargese, Reddy, Rammohan
Therapeutic options for extrahepatic metastases following Liver Transplantation(LT) for Hepatocellular carcinoma(HCC) are limited, and the prognosis remains poor. Innovative blockade of immune checkpoints, such as monoclonal antibodies against programmed death receptor 1 have shown promise in the treatment of solid organ malignancies. Here, we report a case of metastatic HCC after LT, where Pembrolizumab was started following a poor response with Sorafenib. There was a complete radiological response to the drug with no liver graft rejection or dysfunction. This article is protected by copyright. All rights reserved.

Publisher URL: http://doi.org/10.1002/hep.29575

DOI: 10.1002/hep.29575

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.